Uta Griesenbach

5.2k total citations
109 papers, 2.9k citations indexed

About

Uta Griesenbach is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Molecular Biology. According to data from OpenAlex, Uta Griesenbach has authored 109 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 37 papers in Genetics and 27 papers in Molecular Biology. Recurrent topics in Uta Griesenbach's work include Cystic Fibrosis Research Advances (42 papers), Neonatal Respiratory Health Research (41 papers) and Virus-based gene therapy research (35 papers). Uta Griesenbach is often cited by papers focused on Cystic Fibrosis Research Advances (42 papers), Neonatal Respiratory Health Research (41 papers) and Virus-based gene therapy research (35 papers). Uta Griesenbach collaborates with scholars based in United Kingdom, United States and Japan. Uta Griesenbach's co-authors include Eric W.F.W. Alton, D M Geddes, Jane C. Davies, Stefano Ferrari, Duncan M. Geddes, Mamoru Hasegawa, Deborah R. Gill, Stephen C. Hyde, Stefania Xenariou and Raymond Farley and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Biotechnology.

In The Last Decade

Uta Griesenbach

106 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Uta Griesenbach United Kingdom 32 1.4k 1.3k 883 389 323 109 2.9k
Larry G. Johnson United States 27 1.7k 1.2× 1.7k 1.3× 1.1k 1.3× 370 1.0× 344 1.1× 43 3.7k
Gerry McLachlan United Kingdom 22 550 0.4× 871 0.7× 435 0.5× 198 0.5× 127 0.4× 55 1.6k
Joseph Rosenecker Germany 30 435 0.3× 2.6k 2.1× 919 1.0× 297 0.8× 99 0.3× 52 3.4k
Wilfried Dalemans France 32 1.4k 1.0× 1.7k 1.4× 700 0.8× 1.3k 3.2× 74 0.2× 64 4.6k
Susan E. Birket United States 24 891 0.7× 369 0.3× 219 0.2× 203 0.5× 39 0.1× 56 1.7k
Yong Soo Choi South Korea 32 746 0.5× 367 0.3× 379 0.4× 77 0.2× 65 0.2× 142 2.6k
Jocelyne Hinnrasky France 26 1.3k 0.9× 612 0.5× 97 0.1× 86 0.2× 37 0.1× 48 2.0k
Xiaoyu Pan China 26 124 0.1× 834 0.7× 237 0.3× 453 1.2× 53 0.2× 92 2.4k
Richard F. Collins United Kingdom 29 133 0.1× 1.3k 1.0× 651 0.7× 101 0.3× 34 0.1× 58 2.4k
Seong‐Wook Lee South Korea 35 70 0.1× 2.3k 1.8× 291 0.3× 272 0.7× 103 0.3× 136 3.4k

Countries citing papers authored by Uta Griesenbach

Since Specialization
Citations

This map shows the geographic impact of Uta Griesenbach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uta Griesenbach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uta Griesenbach more than expected).

Fields of papers citing papers by Uta Griesenbach

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uta Griesenbach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uta Griesenbach. The network helps show where Uta Griesenbach may publish in the future.

Co-authorship network of co-authors of Uta Griesenbach

This figure shows the co-authorship network connecting the top 25 collaborators of Uta Griesenbach. A scholar is included among the top collaborators of Uta Griesenbach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uta Griesenbach. Uta Griesenbach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Simmonds, Nicholas J., Eric W.F.W. Alton, Uta Griesenbach, et al.. (2025). Increased NFAT and NFκB signalling contribute to the hyperinflammatory phenotype in response to Aspergillus fumigatus in a mouse model of cystic fibrosis. PLoS Pathogens. 21(2). e1012784–e1012784. 2 indexed citations
2.
3.
Davies, Jane C., Deepika Polineni, A. Christopher Boyd, et al.. (2024). Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial. American Journal of Respiratory and Critical Care Medicine. 210(12). 1398–1408. 9 indexed citations
4.
Griesenbach, Uta, Gerry McLachlan, Cédric Cheminay, et al.. (2023). WS17.06 F/HN pseudotyped lentiviral vector-mediated transduction of non-human primates. Journal of Cystic Fibrosis. 22. S33–S33. 1 indexed citations
5.
Allaire, Norm, et al.. (2023). Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis. Journal of Cystic Fibrosis. 22. S39–S44. 15 indexed citations
6.
McLachlan, Gerry, Eric W.F.W. Alton, Alan Boyd, et al.. (2022). Progress in Respiratory Gene Therapy. Human Gene Therapy. 33(17-18). 893–912. 17 indexed citations
7.
Alton, Eric W.F.W., Alan Boyd, Jane C. Davies, et al.. (2016). Genetic medicines for CF: Hype versus reality. Pediatric Pulmonology. 51(S44). S5–S17. 36 indexed citations
8.
Alton, Eric W.F.W., Alan Boyd, David J. Porteous, et al.. (2015). A Phase I/IIa Safety and Efficacy Study of Nebulized Liposome-mediated Gene Therapy for Cystic Fibrosis Supports a Multidose Trial. American Journal of Respiratory and Critical Care Medicine. 192(11). 1389–1392. 40 indexed citations
9.
Griesenbach, Uta, Kamila M Pytel, & Eric W.F.W. Alton. (2015). Cystic Fibrosis Gene Therapy in the UK and Elsewhere. Human Gene Therapy. 26(5). 266–275. 70 indexed citations
10.
Alton, Eric W.F.W., Alan Boyd, Jane C. Davies, et al.. (2014). LARGE-SCALE PRODUCTION OF LENTIVIRAL VECTORS FOR CF LUNG GENE THERAPY. Pediatric Pulmonology. 49. 293–293. 1 indexed citations
11.
Alton, Eric W.F.W., A. Christopher Boyd, Shou‐Hsia Cheng, et al.. (2013). A PHASE 2B DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NON-VIRAL MEDIATED GENE THERAPY FOR CF. Oxford University Research Archive (ORA) (University of Oxford). 2 indexed citations
12.
Griesenbach, Uta, Makoto Inoue, Cuixiang Meng, et al.. (2012). Assessment of F/HN-Pseudotyped Lentivirus as a Clinically Relevant Vector for Lung Gene Therapy. American Journal of Respiratory and Critical Care Medicine. 186(9). 846–856. 79 indexed citations
13.
Alton, Eric W.F.W., Steve Cunningham, Jane C. Davies, et al.. (2010). LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS; THE RUN-IN STUDY. Pediatric Pulmonology. 298–298.
14.
15.
Munkonge, Felix M., Vaksha Amin, Stephen C. Hyde, et al.. (2009). Identification and Functional Characterization of Cytoplasmic Determinants of Plasmid DNA Nuclear Import. Journal of Biological Chemistry. 284(39). 26978–26987. 32 indexed citations
16.
Griesenbach, Uta & A. Christopher Boyd. (2005). Pre-clinical and clinical endpoint assays for cystic fibrosis gene therapy. Journal of Cystic Fibrosis. 4(2). 89–100. 16 indexed citations
17.
Griesenbach, Uta, Chris Kitson, Hazel Painter, et al.. (2004). LacZ siRNA and antisense DNA decrease beta-galactosidase mRNA but not protein expression in the airways of K18-lacZ transgenic mice. The Journal of Gene Medicine. 6(9). 1 indexed citations
18.
Griesenbach, Uta, Stefano Ferrari, D M Geddes, & Eric W.F.W. Alton. (2002). Gene Therapy Progress and Prospects: Cystic fibrosis. Gene Therapy. 9(20). 1344–1350. 53 indexed citations
19.
Gosselin, Diane, Mary M. Stevenson, Elizabeth A. Cowley, et al.. (1998). Impaired Ability of Cftr Knockout Mice to Control Lung Infection with Pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine. 157(4). 1253–1262. 71 indexed citations
20.
Kent, Geraldine, Ray K. Iles, Christine E. Bear, et al.. (1997). Lung disease in mice with cystic fibrosis.. Journal of Clinical Investigation. 100(12). 3060–3069. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Larry G. Johnson Breakdown of academic impact, for papers by Gerry McLachlan Breakdown of academic impact, for papers by Joseph Rosenecker Breakdown of academic impact, for papers by Wilfried Dalemans Breakdown of academic impact, for papers by Susan E. Birket Breakdown of academic impact, for papers by Yong Soo Choi Breakdown of academic impact, for papers by Jocelyne Hinnrasky Breakdown of academic impact, for papers by Xiaoyu Pan Breakdown of academic impact, for papers by Richard F. Collins Breakdown of academic impact, for papers by Seong‐Wook Lee
Rankless by CCL
2026